Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: What can we learn from small studies?

Leukemia Research

Volumn 21, Issue 5, 1997, Pages 435-437

  Evans, W E ^a   Relling, M V ^a   Boyett, J M ^a   Pui, C H ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; DRUG CLEARANCE; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030743149     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00128-2     Document Type: Note

References (13)

1. H. Seidel R. Nygaard P.J. Moe G. Jacobsen B. Lindqvist L. Slordal On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia Leukemia Research 21 1997 429
2. W.E. Evans W.R. Crom C.F. Stewart W.P. Bowman C.-H. Chen M. Abromowitch J.V. Simone Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia Lancet 1 1984 359
3. W.E. Evans W.R. Crom M. Abromowitch R. Dodge A.T. Look George S.L. Bowman C.-H. Pui Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia — identification of a relation between concentration and effect New England Journal of Medicine 314 1986 471
4. B. Camitta D. Mahoney B. Levenlhal S.J. Lauer J.J. Shuster S. Adair C. Civin L. Munoz P. Steuber D. Strother B.A. Kamen Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group study Journal of Clinical Oncology 12 1994 1383
5. W.E. Evans C.-H. Pui M.J.M. Schell TX clearance is more important for intermediate-risk ALL (Letter) Journal of Clinical Oncology 8 1990 1115
6. T.W. Synold M.V. Relling Rivera J.M. Boyell J. Sandlund H. Mahmoud W.M. Crist C.-H. Pui W.E. Evans Blast cell methotrexate-polyglulamate accumulation in vivo differs by lineage, ploidy and methotrexate dose in acute lymphoblastic leukemia Journal of Clinical Investigation 94 1994 1996
7. V.M. Whitehead D.S. Rosenblatt M.J. Vuchich J.J. Shuster A. Witte D. Beaulieu Accumulation of methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis Blood 76 1990 44
8. R. Simon D.G. Altman Statistical aspects of prognostic factor sludies in oncology British Journal of Cancer 69 1994 979
9. A.D.J. Pearson H.A. Amineddine M. Yule S. Mills D.R. Long A.D. Craft J.M. Chessells The influence of serum methotrexate concentrations and drug dosage on outcome of childhood acute lymphoblastic leukemia British Journal of Cancer 64 1991 169
10. M.V. Relling D. Fairclough D. Ayers W.R. Crom J.H. Rodman C.-H. Pui W.E. Evans Patient characteristics associated with high-risk methotrexate concentrations and toxicity Journal of Clinical Oncology 12 1994 1667
11. W.R. Crom A.M. Glynn M. Abromowitch C.-H. Pui W.E. Evans Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance Clinical Pharmacology Therapy 39 1986 592
12. E. Masson M.V. Relling T.W. Synold Q. Liu J.D. Schuetz J.T. Sandlund C.-H. Pui W.E. Evans Accumulation of methotrexate polyglutamates in lymphoblasts is a determinate of antileukemic effects in vivo Journal of Clinical Investigation 97 1996 73
13. C.-H. Pui Childhood leukemias New England Journal of Medicine 332 1995 1618